 Jennifer Barker
Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Addison Disease | 6 | 2012 | 43 | 1.490 |
Why?
| | Diabetes Mellitus, Type 1 | 21 | 2012 | 3628 | 1.400 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2025 | 37 | 1.310 |
Why?
| | Autoantibodies | 15 | 2012 | 1466 | 1.090 |
Why?
| | Autoimmune Diseases | 6 | 2011 | 426 | 0.930 |
Why?
| | Steroid 21-Hydroxylase | 4 | 2012 | 30 | 0.750 |
Why?
| | Endocrine System Diseases | 2 | 2015 | 33 | 0.720 |
Why?
| | Anorexia Nervosa | 1 | 2021 | 84 | 0.660 |
Why?
| | Neonatal Screening | 2 | 2025 | 163 | 0.570 |
Why?
| | Metabolic Diseases | 2 | 2015 | 104 | 0.510 |
Why?
| | Celiac Disease | 4 | 2008 | 286 | 0.480 |
Why?
| | Emergencies | 1 | 2015 | 155 | 0.450 |
Why?
| | Disease Management | 1 | 2015 | 589 | 0.370 |
Why?
| | Turner Syndrome | 2 | 2022 | 52 | 0.360 |
Why?
| | Insulin Antibodies | 2 | 2009 | 105 | 0.340 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2009 | 200 | 0.340 |
Why?
| | Child | 20 | 2025 | 20882 | 0.310 |
Why?
| | HLA-D Antigens | 1 | 2008 | 34 | 0.300 |
Why?
| | HLA-DQ Antigens | 5 | 2009 | 179 | 0.290 |
Why?
| | Hypoglycemia | 1 | 2012 | 427 | 0.280 |
Why?
| | Polymorphism, Genetic | 2 | 2009 | 640 | 0.270 |
Why?
| | Sweetening Agents | 1 | 2007 | 39 | 0.260 |
Why?
| | Insulin-Secreting Cells | 2 | 2008 | 367 | 0.260 |
Why?
| | Preventive Medicine | 1 | 2006 | 41 | 0.260 |
Why?
| | Primary Prevention | 1 | 2007 | 188 | 0.240 |
Why?
| | Humans | 36 | 2025 | 129622 | 0.240 |
Why?
| | Mineralocorticoids | 1 | 2025 | 8 | 0.240 |
Why?
| | Autoimmunity | 5 | 2010 | 862 | 0.240 |
Why?
| | HLA-DR Antigens | 4 | 2009 | 224 | 0.220 |
Why?
| | Disease Progression | 5 | 2012 | 2635 | 0.220 |
Why?
| | HLA-DR3 Antigen | 3 | 2010 | 80 | 0.210 |
Why?
| | Infant, Newborn | 5 | 2025 | 5762 | 0.210 |
Why?
| | Metabolic Syndrome | 1 | 2007 | 339 | 0.210 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 2073 | 0.200 |
Why?
| | Tetany | 1 | 2002 | 3 | 0.200 |
Why?
| | Parental Leave | 1 | 2022 | 23 | 0.200 |
Why?
| | Mass Screening | 3 | 2012 | 1149 | 0.200 |
Why?
| | Child, Preschool | 8 | 2025 | 10518 | 0.200 |
Why?
| | Prediabetic State | 2 | 2009 | 246 | 0.200 |
Why?
| | Adolescent | 13 | 2022 | 20391 | 0.190 |
Why?
| | Insulin | 3 | 2008 | 2326 | 0.190 |
Why?
| | Interferon-alpha | 3 | 2009 | 194 | 0.190 |
Why?
| | Biomarkers | 2 | 2012 | 3973 | 0.190 |
Why?
| | Glucose | 1 | 2007 | 1003 | 0.180 |
Why?
| | Monosomy | 1 | 2021 | 11 | 0.180 |
Why?
| | Sex Chromosome Aberrations | 1 | 2021 | 63 | 0.180 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 39 | 0.180 |
Why?
| | Genotype | 5 | 2011 | 1839 | 0.180 |
Why?
| | Glucocorticoids | 1 | 2025 | 575 | 0.170 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2011 | 18 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 273 | 0.160 |
Why?
| | Liver Diseases | 1 | 2022 | 290 | 0.160 |
Why?
| | Islets of Langerhans | 5 | 2009 | 791 | 0.160 |
Why?
| | Female | 15 | 2025 | 68770 | 0.150 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 133 | 0.150 |
Why?
| | Risk Factors | 6 | 2012 | 9763 | 0.150 |
Why?
| | Genetic Predisposition to Disease | 5 | 2011 | 2282 | 0.140 |
Why?
| | Blood Glucose | 2 | 2009 | 2097 | 0.140 |
Why?
| | Male | 13 | 2025 | 63674 | 0.140 |
Why?
| | Glucose Tolerance Test | 3 | 2009 | 356 | 0.140 |
Why?
| | Hydrocortisone | 2 | 2012 | 307 | 0.130 |
Why?
| | HLA-DR4 Antigen | 2 | 2008 | 78 | 0.130 |
Why?
| | Infant | 4 | 2025 | 9025 | 0.120 |
Why?
| | Time Factors | 4 | 2012 | 6556 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2012 | 1952 | 0.120 |
Why?
| | Administration, Oral | 2 | 2007 | 786 | 0.120 |
Why?
| | Hospitalization | 1 | 2004 | 2070 | 0.110 |
Why?
| | Morbidity | 1 | 2015 | 302 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2012 | 4896 | 0.110 |
Why?
| | Genetic Testing | 2 | 2006 | 428 | 0.100 |
Why?
| | Global Health | 1 | 2015 | 329 | 0.100 |
Why?
| | Proportional Hazards Models | 2 | 2007 | 1201 | 0.100 |
Why?
| | Renin | 1 | 2012 | 32 | 0.100 |
Why?
| | Haplotypes | 3 | 2011 | 475 | 0.100 |
Why?
| | HLA-B Antigens | 1 | 2011 | 62 | 0.090 |
Why?
| | Gene Frequency | 2 | 2010 | 503 | 0.090 |
Why?
| | Endocrine Cells | 1 | 2010 | 7 | 0.090 |
Why?
| | Potassium Channels | 1 | 2011 | 149 | 0.090 |
Why?
| | Prognosis | 2 | 2012 | 3794 | 0.090 |
Why?
| | Alleles | 2 | 2011 | 845 | 0.080 |
Why?
| | Models, Biological | 2 | 2008 | 1722 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | HLA-DQ beta-Chains | 1 | 2009 | 61 | 0.080 |
Why?
| | Graves Disease | 1 | 2009 | 35 | 0.080 |
Why?
| | Homozygote | 1 | 2009 | 193 | 0.080 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 108 | 0.080 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 164 | 0.080 |
Why?
| | Antibody Specificity | 2 | 2007 | 184 | 0.080 |
Why?
| | Fluoroimmunoassay | 1 | 2007 | 3 | 0.070 |
Why?
| | Diet, Gluten-Free | 1 | 2008 | 42 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 107 | 0.070 |
Why?
| | Transglutaminases | 1 | 2008 | 153 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1038 | 0.070 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2006 | 53 | 0.070 |
Why?
| | Immunoglobulin A | 1 | 2008 | 200 | 0.060 |
Why?
| | Adrenal Gland Diseases | 1 | 2006 | 6 | 0.060 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2006 | 15 | 0.060 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 28 | 0.060 |
Why?
| | Thyroglobulin | 1 | 2005 | 27 | 0.060 |
Why?
| | Autoantigens | 1 | 2008 | 417 | 0.060 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 120 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 14 | 0.060 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2004 | 45 | 0.060 |
Why?
| | Organ Specificity | 1 | 2005 | 296 | 0.060 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2004 | 62 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2004 | 114 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2008 | 328 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 1838 | 0.060 |
Why?
| | Biological Evolution | 1 | 2008 | 427 | 0.060 |
Why?
| | Glutamate Decarboxylase | 1 | 2004 | 166 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 271 | 0.050 |
Why?
| | HLA Antigens | 1 | 2005 | 234 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 168 | 0.050 |
Why?
| | Cohort Studies | 2 | 2022 | 5420 | 0.050 |
Why?
| | Immune Tolerance | 1 | 2005 | 355 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2007 | 3083 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 1004 | 0.050 |
Why?
| | Karyotype | 1 | 2021 | 17 | 0.050 |
Why?
| | Chromosomes, Human, Y | 1 | 2021 | 20 | 0.050 |
Why?
| | Genitalia | 1 | 2021 | 30 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1001 | 0.040 |
Why?
| | Mosaicism | 1 | 2021 | 71 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1622 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 280 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 315 | 0.040 |
Why?
| | Bone and Bones | 1 | 2002 | 299 | 0.040 |
Why?
| | Proteins | 1 | 2004 | 942 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 437 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 5066 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2007 | 1220 | 0.040 |
Why?
| | Young Adult | 2 | 2012 | 12426 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2564 | 0.040 |
Why?
| | Patient Compliance | 1 | 2002 | 565 | 0.040 |
Why?
| | Animals | 4 | 2008 | 35360 | 0.040 |
Why?
| | Pedigree | 2 | 2010 | 487 | 0.030 |
Why?
| | Phenotype | 2 | 2021 | 3076 | 0.030 |
Why?
| | Mice | 3 | 2008 | 16937 | 0.030 |
Why?
| | Prospective Studies | 2 | 2006 | 7131 | 0.030 |
Why?
| | Reference Values | 2 | 2009 | 793 | 0.030 |
Why?
| | Adult | 5 | 2011 | 35572 | 0.030 |
Why?
| | Parents | 1 | 2022 | 1309 | 0.030 |
Why?
| | Colorado | 1 | 2004 | 4420 | 0.030 |
Why?
| | HLA-B15 Antigen | 1 | 2011 | 13 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 87 | 0.020 |
Why?
| | HLA-B8 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 341 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 164 | 0.020 |
Why?
| | Middle Aged | 3 | 2009 | 31150 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5401 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 11 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 20 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2004 | 10226 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2010 | 257 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 231 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 387 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 51 | 0.020 |
Why?
| | Europium | 1 | 2007 | 2 | 0.020 |
Why?
| | Fluorometry | 1 | 2007 | 17 | 0.020 |
Why?
| | Luminescent Agents | 1 | 2007 | 7 | 0.020 |
Why?
| | Risk | 1 | 2010 | 854 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 178 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 51 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2008 | 588 | 0.020 |
Why?
| | United States | 1 | 2022 | 13900 | 0.020 |
Why?
| | Aged | 1 | 2004 | 22099 | 0.020 |
Why?
| | Lung Diseases | 1 | 2011 | 742 | 0.010 |
Why?
| | Family | 1 | 2009 | 657 | 0.010 |
Why?
| | Family Health | 1 | 2005 | 198 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 601 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1367 | 0.010 |
Why?
| | Survival Rate | 1 | 2006 | 1877 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 833 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1720 | 0.010 |
Why?
|
|
Barker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|